 Actually, there is no structured collaboration with regulatory agencies in Sweden except for the dialogue meeting where they invite us for. But we have kind of taken, we have been pushing so much for several years to have a more structured patient involvement in the process. So, but for two years ago, we kind of took another approach. So we tried to convince the politicians in Sweden, instead that this patient involvement is really necessary to be able to you know, transform science and research to clinical trials to patient access. Because we did a project actually to try to convince the regulatory body and also the politician that this patient involvement is really necessary. And in that project, we had dialogue meetings. We had roundtable discussions with all kind of stakeholders, not just the regulatory body. It was the pharma company that were involved. It was the clinicians that were involved. It was politicians and decision makers and payers and you know, all kind of stakeholders. And we also did a report, a blood cancer report. We had a debate article about it and we also had a survey with questionnaires to 400 politicians in Sweden, both national and regional. And we were also doing three films. One were the politicians stating that this patient involvement is really necessary. She used to be in the health care and social care department in Sweden. And also with a CLL patient that had been in a clinical trial and also with the Miloma professor, all of them stating the necessary and the portals for patient getting access to clinical trials and also getting access to new innovative treatments. I think it's crucial to be able actually to take science to the clinical trial and from that to really implement which is the part where we really have problems actually. And with no patient access, there is no actually no innovation. So I think it's really crucial to be able to have access to new innovations. We really need this structure form of collaboration and patient involvement. Not just you know, taking the box exercise. Well I'm not happy at all the way it is, but I think the politicians, they have recently had TLV, which is one of the HTA bodies in Sweden, to do this investigation concerning combination therapy, concerning pricing, new pricing models, ATMP, and also rare diseases. So I think that is kind of a start. And also we see that you know, the stakeholders or the politician, they are more aware of that we need a more structure form of a patient involvement. And for the moment, there is only one patient advocate that is in the board of TLV and she is support too. It's not just the cancer, it's rheumatology. It's dermatology, it's heart and lung disease, it's allergies, it's all over and she's supposed to knew everything. And well, you can't be that educated, so no one can about everything. So and what we really have been advocating for is that we want a patient advocate, we want an expert patient, that they change from what kind of disease area they are talking about. And we also want them to be in the process to be able to do a written submission, and also to be able to appeal the decision, if the decision isn't in line with what the patient that vote the organization think. So what we, our organization has started to do, although we are not, you know, invited in the way that we'd like to be, is to do the written submission when there is, you know, when they are doing the health economy evaluation concerning our disease area. So at least we do it, although we are not asked to do it.